Roivant Sciences Ltd. Q4 FY2024 earnings call

• Pipeline and Clinical Progress: 2025 is a crucial year with data generated for Batoclimab in Myasthenia Gravis and CIDP, upcoming registrational data from Brepocitinib in dermatomyositis, and ongoing clinical execution in main franchises. IMVT-1402 is a key anti-FcRn antibody with multiple indications. • Events: On June 17, an Investor event will be held for DM disease education and trial design details. • LNP Litigation: In summary judgment phase, moving towards U.S. jury trial, with international trials and Pfizer case ongoing. • Financial Update: Solid quarter with just under $5 billion in cash, net use of cash around $150-160 million, and continuing share repurchase.

No specific financial performance by product segment with absolute terms and revenue contribution % provided in the transcript.

• Upcoming data from Brepocitinib including pivotal and DM readouts within 18-24 months. • IMVT-1402 studies with data expected in 2026-2027 including CLE study and registrational data in multiple indications. • LNP litigation milestones with summary judgment phase ongoing and jury trial TBD. • International trials and Pfizer case expected to progress.

• Uncertainties in LNP litigation outcomes, including summary judgment and jury trial timelines. • Clinical trial risks related to data readouts and potential variability in placebo responses. • Market competition in the FcRn space affecting pricing and indication prioritization.

Q: How should we think through a win scenario in DM for Brepocitinib?

A: A positive study with statistically significant separation from placebo on TIS and a low P-value is key, given high unmet medical need in DM patients.

Q: Could you provide color on the LNP litigation against Moderna regarding case narrowing?

A: It's a normal part of patent cases to narrow claims before trial, focusing on presenting a clear case to the jury.

Q: Comment on the pending Pfizer LNP litigation Markman decision?

A: The judge has discretion on timeline, and it may come later this year but no specific signal from timing.

Q: How are you thinking about pricing in the FcRn space with increasing competition?

A: Flexibility in pricing due to multiple factors including ability to deliver different doses, unmet need in indications, and compatibility with competitor pricing models.

Q: Details on the CIDP study design for IMVT-1402?

A: Design avoids washouts for patient friendliness, leveraging improved patient selection in the field, and data to position for commercial success.